Devyser strengthens U.S. market presence with CMS pricing for PrenatalDetect RHD test
Devyser today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its...
Oncology | September 7, 2022
With cancer identified as the leading cause of death in high-income countries, early identification and treatment of cancer, and potential cancer-causing genetic variants, is essential. As the second most common cancer worldwide, and the most frequently diagnosed cancer among women, breast cancer nonetheless has a high survival rate if diagnosed and treated.
Read more about the simple identification of both BRCA1 and BRCA2 genes in the whitepaper:
Next Generation Sequencing – Full gene sequencing of BRCA1 and BRCA2
Devyser today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its...
Read More
Devyser today announced the enrollment of the first patient in its Devyser Accept cfDNA clinical...
Read More
Devyser, a pioneer in advanced genetic testing solutions, is pleased to announce that its...
Read More
Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation...
Read More